Description
Combined IAP antagonism and immunotherapy for cancer treatment
Amendment chain · 2 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $937,126 at start, $339,709 after amendment #1 (−$597,417).
- #02018-10-01$937,126
- #12019-09-30$339,709-$597,417
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2018-10-01(start date) | $937,126 | — | Combined IAP antagonism and immunotherapy for cancer treatment |
| #1 amendment | 2019-09-30 | $339,709 | −$597,417 | Combined IAP antagonism and immunotherapy for cancer treatment |
Related records · 3
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2025-2026-Q1-01711 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Research in Priority Areas | $1,091 | FY2026 |
| 236-2019-2020-Q2-00450 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $2,948,700 | FY2020 |
| 236-2015-2016-Q4-00063 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $100,000 | FY2016 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2018-2019-Q3-00878 · retrieved 2026-11-14.